Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
very Fat dildos!
Popular Articles

The 454 Genome Sequencing System Detects A Novel Virus Responsible For South African Hemorrhagic Fever Outbreak
A study published online in PLoS Pathogens reports that researchers at Columbia University, the South African National Health Laboratory Services, the US Centers for Disease Control, and 454 Life Sciences have discovered a new virus that is responsible for a highly fatal hemorrhagic fever outbreak in Zambia and South Africa late 2008(1). The previously unknown arenavirus, which is distantly related to the Lassa virus and Lymphocytic choriomeningitis virus, was characterized using the rapid and sensitive sequencing technology of 454 Life Sciences. The new species, named "Lujo virus" for the geographic origin of the outbreak (Lusaka, Zambia and Johannesburg, South Africa), is the first hemorrhagic fever-associated arenavirus from Africa identified in the past three decades. Characterization of the novel virus confirms the utility of unbiased high-throughput sequencing for pathogen discovery and provides an opportunity for public health efforts to quickly curb emerging viral pandemics in the future.
diet pills Prezzi dentisti croazia
Let GPs Order MRI Under Medicare, Australia
Patients would spend less time waiting for medical testing and treatment if the Government introduced Medicare rebates for GP-referred MRI (Magnetic Resonance Imaging) and diagnostic testing in GP surgeries, the AMA said today.
News of the day
MPS Clarifies Indemnity Arrangements For GPs During A Pandemic Flu Outbreak
Medical Protection Society (MPS) GP members, who are expected to work outside of their normal duties during a pandemic flu, should feel confident that they can turn to the MPS for assistance, in the event they are subject to a clinical negligence claim or other medicolegal matter such as a complaint.
Mental Health

Implanted Defibrillators: New Recommendations For Drivers With ICDs

Patients with an Implantable Cardioverter Defibrillator (ICD) have an ongoing risk of sudden incapacitation that might cause harm to others while driving a car. Driving restrictions are imposed making these recommendations an important guideline for patients. A consensus statement with recommendations for drivers with ICD"s was presented at a press conference at the Europace 2009 meeting, in Berlin, Germany on Sunday 21 June. A team of twelve experts from the European Heart Rhythm Association (EHRA), the Council on Cardiovascular Nursing and Allied Professions in ESC (CCNAP) and the Section Cardiac Rehabilitation of the European Association of Cardiovascular Prevention and Rehabilitation, reviewed the literature, assessed the risk and issued a consensus statement. "Driving restrictions vary across different countries in Europe. We hope the document may serve as an instrument for European and National regulatory authorities to formulate uniform driving regulations", explained Johan Vijgen, chairperson of the task force*. "Driving restrictions are perceived as difficult for patients and their family and have an immediate consequence for their lifestyle. In addition to the psychological and societal impact, the driving ban may also pose a considerable impact on employment and education and thereby economic status", said Vijgen. The document presents recommendations for private driving (group 1) and professional driving (group 2). Definitions of the European Council Directives (80/1263/EEC) and (91/439/EEC) are used. * Group 1: drivers of ordinary motor cycles, cars, and other small vehicles with or without a trailer. * Group 2: drivers of vehicles over 3.5 metric tonnes or passenger carrying vehicles exceeding eight seats excluding the driver. Since the introduction of the ICD in the early 1980s, multiple trials have demonstrated the efficacy of ICDs for the prevention of sudden arrhythmic death. This resulted in a significant increase in the number of implants. In Western Europe alone, 63000 ICDs were implanted in 2006 and 85500 ICDs in 2008. Many patients are currently implanted for primary prevention (treatment of patients at risk for life-threatening arrhythmias who have never had sustained ventricular arrhythmias). The risk for sudden incapacitation is lower in these patients. Therefore, driving restriction should be less strict for these patients, than for patients implanted for secondary prevention (those who have survived a life-threatening arrhythmia). "Patients and their families should receive adequate discharge education and standardized information on driving recommendations. This should result in a better adherence to the recommendations. It should be emphasized that the risk is mainly a consequence of the underlying condition and not of the presence of the ICD", explained Prof Vijgen. The consensus statement will be published in the June issue of Europace, the official journal of the European Heart Rhythm Association. *Members of the task force include Johan Vijgen (chairperson) Belgium, Gianluca Botto (Italy) , John Camm (United Kingdom), Carl-Johan Hoijer (Sweden), Werner Jung (Germany), Jean-Yves Le Heuzey (France), Andrzej Lubinski (Poland), Tone M. Norekvç¥l (Norway), Maurizio Santomauro (Italy), Martin Schalij (The Netherlands), Jean-Paul Schmid (Switzerland), and Panos Vardas (Greece) Notes: EHRA, the European Heart Rhythm Association, aims to serve as the leading organisation in the field of arrhythmias and electrophysiology in Europe, and to attract physicians from all of Europe and beyond to foster the development of this area of expertise. EHRA is a registered branch of the European Society of Cardiology (ESC). EHRA is based in Sophia Antipolis, France. The European Society of Cardiology (ESC) represents more than 50,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. Information on the scientific programme ESC Press Office European Society of Cardiology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009